EPIDUO Drug Patent Profile

Which patents cover Epiduo, and when can generic versions of Epiduo launch?

Epiduo is a drug marketed by Galderma Labs Lp and Galderma Labs and is included in two NDAs. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has thirty-five patent family members in twenty-two countries.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epiduo

A generic version of EPIDUO was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for EPIDUO

International Patents:	35
US Patents:	3
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	31
Patent Applications:	66
Drug Prices:	Drug price information for EPIDUO
Drug Sales Revenues:	Drug sales revenues for EPIDUO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDUO
What excipients (inactive ingredients) are in EPIDUO?	EPIDUO excipients list
DailyMed Link:	EPIDUO at DailyMed

See drug prices for EPIDUO

See drug sales revenues for EPIDUO

Recent Clinical Trials for EPIDUO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	Phase 2
Mahidol University	Phase 2
Beiersdorf	Phase 2

See all EPIDUO clinical trials

Pharmacology for EPIDUO

Drug Class

Retinoid

Paragraph IV (Patent) Challenges for EPIDUO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO	Gel	adapalene; benzoyl peroxide	0.1%/2.5%	022320	1	2011-12-30

US Patents and Regulatory Information for EPIDUO

EPIDUO is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,080,537
Galderma Labs	EPIDUO FORTE	adapalene; benzoyl peroxide	GEL;TOPICAL	207917-001	Jul 15, 2015	AB	RX	Yes	Yes
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,129,362
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,071,644		Y

Expired US Patents for EPIDUO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	4,717,720
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	8,809,305
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	RE34440
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	7,820,186
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	8,241,649

International Patents for EPIDUO

When does loss-of-exclusivity occur for EPIDUO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

France

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008209730
Lithuania	2450035
Finland	88793
Russian Federation	2009132502
European Patent Office	1458369	GEL COMPRENANT AU MOINS UN RETINOIDE ET DU PEROXYDE DE BENZOYLE (GEL COMPRISING AT LEAST A RETINOID AND BENZOYL PEROXIDE)

Supplementary Protection Certificates for EPIDUO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	122008000041	Germany		PRODUCT NAME: ADAPALEN IN KOMBINATION MIT BENZOYLPEROXID; NAT. REGISTRATION NO/DATE: 67913.00.00 20080229; FIRST REGISTRATION: DAENEMARK 40440 20071218
0199636	300209	Netherlands		300209, 20060411, EXPIRES: 20070702
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	380	Finland

Market Dynamics and Financial Trajectory for EPIDUO

Last updated: February 19, 2026

What is EPIDUO and how does it fit into the dermatology market?

EPIDUO, a topical combination of clindamycin phosphate and tretinoin, is approved for the treatment of acne vulgaris. Its formulation combines an antibiotic with a retinoid, targeting multiple pathogenic factors of acne: bacterial proliferation, inflammation, and keratinocyte hyperplasia. Industry estimates value the global acne treatment market at approximately $4.2 billion in 2022, with EPIDUO representing a significant segment primarily in North America and Western Europe.

How has EPIDUO performed historically in terms of sales and market penetration?

EPIDUO was approved by the FDA in 2016. In 2020, it generated approximately $240 million worldwide, according to IQVIA data. U.S. sales reached about $180 million, with these figures reflecting its status as a premium treatment option versus monotherapies. The drug's growth was driven by increased dermatologist prescriptions and patient adherence benefits due to its fixed-dose combination.

The drug's market penetration faces competition from both generic formulations and other combination therapies, with generic versions of tretinoin and clindamycin available since 2018. Despite this, EPIDUO retains a strong position due to its branded formulation's convenience and proven efficacy.

What factors influence the market dynamics for EPIDUO?

Competition and generics

The expiration of patents on the core components has led to an influx of generic alternatives. Generic sales in acne treatment grew by approximately 8% CAGR between 2019 and 2022. EPIDUO's market share declined marginally as a result, but its brand recognition and prescription habits sustain its sales.

Prescriber and patient preferences

Dermatologists prefer fixed-dose combinations for simplified regimens. EPIDUO’s convenience supports adherence, but prescriber preference shifts towards other drugs with better safety profiles or fewer side effects have emerged, especially with the rise of systemic treatments and newer topical agents.

Regulatory and reimbursement policies

Insurance coverage and formulary positioning significantly impact sales. EPIDUO’s inclusion in preferred drug lists increases patient access, but formulary restrictions in certain markets limit uptake. Pricing flexibility is necessary to counter the commoditization of generic alternatives.

Market expansion opportunities

The drug remains off-label in certain markets, presenting opportunities. Asia-Pacific markets, where acne prevalence is high, have limited EPIDUO penetration due to regulatory hurdles and local competitors. Expanding into dermatology clinics and via direct-to-consumer advertising could boost revenues.

What is the competitive landscape in the acne pharmacotherapy segment?

Drug	Type	Approval Year	Market Share (2022)	Key Differentiators
EPIDUO	Fixed-dose topical combo	2016	15% (U.S.)	Efficacy, adherence, branding
Differin (adapalene)	Topical retinoid	2016	20%	Over-the-counter availability
Benzoyl peroxide	Topical antibacterial	1940s	10%	Cost-effective, OTC
Duac (clindamycin+benzoyl peroxide)	Topical combination	2012	12%	Established efficacy, formulary presence

The competitive positioning of EPIDUO relies on its combination therapy approach, but generic substitutes and emerging agents threaten its market share.

What are the financial expectations going forward?

Projected revenues for EPIDUO will likely experience moderate growth through 2025. Key assumptions:

• Market CAGR of 2-3%, driven by increased dermatologist prescribing.
• Market share stabilization due to generic pressures.
• Price adjustments to maintain profitability.
• Expansion into emerging markets with unmet demand.

Estimated revenues for 2023 are forecasted at approximately $240-$250 million globally. By 2025, revenues could reach $260-$280 million, assuming steady market conditions.

What are the primary risks and opportunities for EPIDUO’s financial trajectory?

Risks

• Patent challenges and the influx of generics could erode margins.
• Competition from newer topical agents, such as topical antimicrobials and novel retinoids.
• Regulatory delays in key markets or reforms affecting reimbursement.

Opportunities

• Expanding indications or delivering new formulations.
• Increasing adoption via dermatological education campaigns.
• Entering markets with high unmet demand, such as China or India.

Key Takeaways

• EPIDUO’s sales efficiency faces headwinds from generics, prompting reliance on branding and formulary strategies.
• Market growth hinges on prescriber acceptance, formulary inclusion, and geographic expansion.
• The global acne treatment market remains competitive, with multiple established and emerging therapies.

FAQs

1. What is the main advantage of EPIDUO over monotherapies?
It combines an antibiotic and a retinoid, providing a multipronged approach that improves efficacy and patient adherence.

2. How are generic versions impacting EPIDUO’s market share?
They limit EPIDUO’s growth and exert downward pressure on pricing but do not eliminate its brand loyalty among prescribers.

3. Which markets present the greatest growth potential for EPIDUO?
Emerging markets in Asia-Pacific, notably China and India, and expanding dermatology clinics in Europe and Latin America.

4. What regulatory hurdles could affect EPIDUO’s expansion?
Approval delays and reimbursement restrictions in countries with stringent drug registration processes can slow market penetration.

5. What strategies can drive future revenue for EPIDUO?
Enhancing formulary positioning, developing new formulations, and targeted marketing in high-growth regions.

References

1. IQVIA. (2022). Pharmaceutical Market Data.
2. U.S. Food and Drug Administration. (2016). FDA Approval of EPIDUO.
3. Statista. (2022). Global Acne Treatment Market.
4. EvaluatePharma. (2022). Top Dermatology Drugs.
5. Company Financial Reports. (2020-2022). Epiduo Sales and Market Data.